Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
ConditionLung Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorUniversity of Colorado, Denver
About this trial
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.
Eligibility criteria
Qualifiers
Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
Aged 18 years or older
Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
Patients must have the ability to understand and willingness to sign an informed consent document.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1University of Colorado Cancer Center80045, AuroraColorado, United States
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Cancer Institute (NCI)
Collaborator
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov